Innovative AI Platform SOM Biotech leverages a proprietary Artificial Intelligence platform for drug discovery, positioning it as a leader in technology-driven biopharmaceutical development, which may appeal to partners seeking cutting-edge research collaborations.

Focus on Orphan Diseases The company's emphasis on neurological orphan diseases offers opportunities to collaborate with specialized healthcare providers and biotech firms targeting rare conditions with unmet treatment needs.

Strategic Partnerships Recent collaborations with the University of Minnesota and Ewha Womans University showcase SOM's openness to academic partnerships, presenting potential avenues for license agreements or joint research projects.

Recent Leadership Expansion Adding seasoned professionals like George G. Montgomery as Strategic Corporate Advisor and new CFO Marc Casellas indicates a focus on strategic growth and financial stability, beneficial for engaging investors or corporate partners.

Early Commercial Stage With a revenue range of $0-1M and active clinical-stage projects including COVID-19 drug candidates, SOM offers opportunities for early-stage collaborations, funding, and partnership to scale promising therapeutic candidates.